Gilead Sciences, Inc. (GILD) is Rock Point Advisors LLC’s 4th Largest Position

Rock Point Advisors LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 116,296 shares of the biopharmaceutical company’s stock after selling 7,481 shares during the quarter. Gilead Sciences comprises about 4.4% of Rock Point Advisors LLC’s holdings, making the stock its 4th largest position. Rock Point Advisors LLC owned approximately 8,897.93% of Gilead Sciences worth $9,422,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC lifted its position in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares during the period. Vanguard Group Inc. lifted its position in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Northern Trust Corp lifted its position in Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares during the period. Toronto Dominion Bank lifted its position in Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after purchasing an additional 75,364 shares during the period. Finally, Fagan Associates Inc. lifted its position in Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 845 shares during the period. 75.95% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Gilead Sciences, Inc. (GILD) opened at $79.02 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The stock has a market cap of $103,190.00, a price-to-earnings ratio of 8.99, a PEG ratio of -1.68 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the previous year, the company earned $2.75 EPS. The business’s quarterly revenue was down 13.2% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio is presently 23.66%.

In related news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the sale, the insider now directly owns 3,070,099 shares of the company’s stock, valued at approximately $230,656,537.87. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders have sold a total of 461,666 shares of company stock valued at $34,072,567 over the last three months. Corporate insiders own 1.30% of the company’s stock.

A number of equities research analysts have recently issued reports on GILD shares. BMO Capital Markets reiterated a “hold” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Friday, October 20th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Morgan Stanley restated an “equal weight” rating and set a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. Bank of America cut their price objective on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research report on Wednesday, October 4th. Finally, Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $85.03.

TRADEMARK VIOLATION NOTICE: This piece was first reported by BBNS and is the property of of BBNS. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://baseballnewssource.com/markets/gilead-sciences-inc-gild-holdings-lowered-by-rock-point-advisors-llc/1819528.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.